Ogliren is an oral capsule formulation used for the treatment of type 2 diabetes mellitus.
I. Basic Administration Guidelines
1. Route of Administration
(1) Ogliren is taken orally, and should be swallowed whole with an adequate amount of water.
(2) The capsule must not be chewed, crushed, or opened before ingestion, to avoid affecting drug release/absorption or irritating the oral mucosa.
(3) It is recommended to take the medication at the same time each day to help maintain stable blood concentrations.
2. Taking with or without Food
(1) If gastrointestinal discomfort occurs after taking the drug, it may be tried with or immediately after meals to alleviate symptoms such as nausea and diarrhea.
(2) However, the dose should not be reduced or discontinued arbitrarily due to such discomfort.
3. Missed Dose Management
(1) If a dose is forgotten, and it is still early before the next scheduled dose, it can be taken as soon as remembered; if it is close to the next dose, skip the missed dose and take the next dose on time.
(2) Do not take a double dose to make up for a missed one, as this increases the risk of adverse reactions.
II. Dose Titration Principles
1. Starting Dose and Maintenance Dose
(1) Ogliren is usually initiated with a dose-escalation regimen, starting from a low dose and gradually increasing to the target maintenance dose after the patient tolerates it.
(2) The specific starting dose and maintenance dose should be individualized by the physician based on the patient's blood glucose levels, tolerability, and therapeutic response; patients must not adjust them on their own.
2. Dose Considerations in Combination Therapy
(1) When Ogliren is used in combination with sulfonylureas or insulin, the risk of hypoglycemia increases.
(2) In such cases, the dose of the sulfonylurea or insulin may need to be appropriately reduced to lower the possibility of hypoglycemia.
(3) Any adjustment to the combination regimen must be made under the guidance of a physician.
3. Maximum Recommended Dose
(1) Ogliren has a daily maximum recommended dose limit; exceeding this limit does not provide additional glycemic benefit but increases the risk of adverse reactions.
(2) Patients should be aware of their prescribed dose and confirm that it does not exceed the safe range.
III. Precautions for Use
1. Use in Children and Adolescents
Ogliren is not indicated in children under 10 years of age; use in adolescents should be strictly under the guidance of a specialist.
2. Dose Adjustment in Hepatic or Renal Impairment
(1) In such patients, if medication is required, it may be started at a lower dose and with enhanced monitoring.
(2) Patients with mild impairment may generally use the usual dose, but this still requires physician evaluation.
3. Discontinuation Precautions
(1) Ogliren is usually taken regularly over the long term to maintain glycemic control.
(2) If discontinuation is needed, it should be done gradually under medical supervision, with an alternative treatment plan established.
(3) Abrupt withdrawal may lead to elevated blood glucose.
(4) However, if serious adverse events such as acute pancreatitis or severe allergic reactions occur, the drug must be stopped immediately and emergency management initiated.
4. Switching Therapy
(1) If a patient is currently using other glucose-lowering agents, conversion to Ogliren requires consideration of cross-reactivity and dose equivalence calculations.
(2) Self-switching of medication is not recommended; the conversion plan should be developed by a physician, with a washout or overlap period set if necessary.
